[go: up one dir, main page]

GB202016758D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB202016758D0
GB202016758D0 GBGB2016758.1A GB202016758A GB202016758D0 GB 202016758 D0 GB202016758 D0 GB 202016758D0 GB 202016758 A GB202016758 A GB 202016758A GB 202016758 D0 GB202016758 D0 GB 202016758D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2016758.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Priority to GBGB2016758.1A priority Critical patent/GB202016758D0/en
Publication of GB202016758D0 publication Critical patent/GB202016758D0/en
Priority to ES21732212T priority patent/ES3040433T3/en
Priority to AU2021286831A priority patent/AU2021286831A1/en
Priority to CA3186148A priority patent/CA3186148A1/en
Priority to SI202130328T priority patent/SI4161929T1/en
Priority to HRP20250891TT priority patent/HRP20250891T1/en
Priority to PCT/EP2021/065112 priority patent/WO2021249909A1/en
Priority to MDE20230409T priority patent/MD4161929T2/en
Priority to RS20250744A priority patent/RS67140B1/en
Priority to DK21732212.2T priority patent/DK4161929T3/en
Priority to PT217322122T priority patent/PT4161929T/en
Priority to CN202180040683.1A priority patent/CN115836073B/en
Priority to JP2022575399A priority patent/JP2023528087A/en
Priority to MX2022015608A priority patent/MX2022015608A/en
Priority to BR112022024794A priority patent/BR112022024794A2/en
Priority to US18/008,352 priority patent/US20230312580A1/en
Priority to KR1020237000509A priority patent/KR20230022215A/en
Priority to SM20250343T priority patent/SMT202500343T1/en
Priority to EP21732212.2A priority patent/EP4161929B1/en
Priority to FIEP21732212.2T priority patent/FI4161929T3/en
Priority to LTEPPCT/EP2021/065112T priority patent/LT4161929T/en
Priority to CONC2022/0017233A priority patent/CO2022017233A2/en
Priority to IL298785A priority patent/IL298785B1/en
Priority to ZA2022/13877A priority patent/ZA202213877B/en
Ceased legal-status Critical Current

Links

GBGB2016758.1A 2020-06-08 2020-10-22 Novel compounds Ceased GB202016758D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB2016758.1A GB202016758D0 (en) 2020-10-22 2020-10-22 Novel compounds
LTEPPCT/EP2021/065112T LT4161929T (en) 2020-06-08 2021-06-07 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4- METHYLHEXAHYDROPYRROLO[3,4-B]PYRROLO-5(1H)-CARBONITRILE AS A USP30 INHIBITOR FOR THE TREATMENT OF MITOCHONDRAL DYSFUNCTION, CANCER AND FIBROSIS
PT217322122T PT4161929T (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
JP2022575399A JP2023528087A (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3] as USP30 inhibitors used in the treatment of mitochondrial dysfunction, cancer, and fibrosis ,4-b]pyrrole-5(1H)-carbonitrile
CA3186148A CA3186148A1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
SI202130328T SI4161929T1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
HRP20250891TT HRP20250891T1 (en) 2020-06-08 2021-06-07 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYRROLE-5(1H)-CARBONITRILE AS A USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRAL DYSFUNCTION, CANCER AND FIBROSIS
PCT/EP2021/065112 WO2021249909A1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
MDE20230409T MD4161929T2 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
RS20250744A RS67140B1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
DK21732212.2T DK4161929T3 (en) 2020-06-08 2021-06-07 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYRROLE-5(1H)-CARBONITRILE AS A USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRAL DYSFUNCTION, CANCER AND FIBROSIS
ES21732212T ES3040433T3 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
CN202180040683.1A CN115836073B (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-B]pyrrole-5(1H)-carbonitrile as USP30 inhibitor for the treatment of mitochondrial dysfunction, cancer and fibrosis
AU2021286831A AU2021286831A1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4- methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile as USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
MX2022015608A MX2022015608A (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydrop yrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis.
BR112022024794A BR112022024794A2 (en) 2020-06-08 2021-06-07 HEXAHYDROPYROLO[3,4-B]PYROLE-5(1H)-CARBONITRILS WITH ACTIVITY AS USP30 INHIBITORS FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS
US18/008,352 US20230312580A1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
KR1020237000509A KR20230022215A (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3 as an inhibitor of USP30 for use in the treatment of mitochondrial dysfunction, cancer and fibrosis ,4-b] pyrrole-5 (1H) -carbonitrile
SM20250343T SMT202500343T1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
EP21732212.2A EP4161929B1 (en) 2020-06-08 2021-06-07 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
FIEP21732212.2T FI4161929T3 (en) 2020-06-08 2021-06-07 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYRROLE-5(1H)-CARBONITRILE AS A USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRAL DYSFUNCTION, CANCER AND FIBROSIS
CONC2022/0017233A CO2022017233A2 (en) 2020-06-08 2022-11-30 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as a usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
IL298785A IL298785B1 (en) 2020-06-08 2022-12-04 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
ZA2022/13877A ZA202213877B (en) 2020-06-08 2022-12-21 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2016758.1A GB202016758D0 (en) 2020-10-22 2020-10-22 Novel compounds

Publications (1)

Publication Number Publication Date
GB202016758D0 true GB202016758D0 (en) 2020-12-09

Family

ID=73727146

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2016758.1A Ceased GB202016758D0 (en) 2020-06-08 2020-10-22 Novel compounds

Country Status (1)

Country Link
GB (1) GB202016758D0 (en)

Similar Documents

Publication Publication Date Title
GB202115158D0 (en) Novel compounds
GB202013728D0 (en) Novel compounds
GB202115156D0 (en) Novel compounds
GB2605894B (en) Novel compounds
GB2637108B (en) Novel Compounds
GB202101734D0 (en) Novel Compounds
GB202115150D0 (en) Novel compounds
GB202016800D0 (en) Novel compounds
GB202014341D0 (en) Novel compounds
GB202409732D0 (en) Novel compounds
GB202118096D0 (en) Novel compounds
GB202117366D0 (en) Novel compounds
GB202113016D0 (en) Novel compounds
GB202110809D0 (en) Novel compounds
GB202109446D0 (en) Novel compounds
GB202108873D0 (en) Novel compounds
GB202106872D0 (en) Novel compounds
GB202106871D0 (en) Novel compounds
GB202101935D0 (en) Novel compounds
GB202101573D0 (en) Novel compounds
GB202101280D0 (en) Novel compounds
GB202019588D0 (en) Novel Compounds
GB202016758D0 (en) Novel compounds
GB202016791D0 (en) Novel compounds
GB202016785D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)